ROSSELL-TECHSYS
10.11.2021 18:54:04 CET | Business Wire | Press release
Rossell Techsys has been awarded a contract with Lockheed Martin to build Electrical Wire Harness and Interconnect System (EWIS) parts in support of Lockheed Martin’s MH-60R aircraft that are being supplied to the Indian Navy. Last year, India signed a USD $2.1 billion deal with the United States Government as part of its Foreign Military Sales program for the purchase of 24 Lockheed Martin anti-submarine MH-60R helicopters. The first three of these MH-60R all-weather helicopters, which can support multiple missions with state-of-the-art avionics and sensors, have been delivered to the Indian Navy and are currently undergoing pilot and crew training in the United States. The delivery of 24 helicopters will be completed in five years from the time the deal was concluded. The helicopters will be modified with a variety of "India-unique" equipment and weapons. The induction of these fourth-generation MH-60Rs is expected to further enhance the Indian Navy's three-dimensional capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110006132/en/
“We are honoured to have been selected to manufacture wire harnesses for the MH-60R, an important equipment for India. We are committed to producing high-quality parts, on time, from India, furthering India’s growing strength in manufacturing to global standards and contributing to Aatmanirbhar Bharat ,” said Mr. Prabhat Kumar Bhagvandas, Chief Executive Officer, Rossell Techsys.
As part of the contract received from Lockheed Martin, Rossell Techsys shall perform “Build to Print” (BTP) manufacture of the wire harnesses that will be installed on the MH-60R. Manufacture of these parts is being performed in the “Center of Excellence” (COE), set up by Rossell Techsys for Lockheed Martin platforms. The manufacture of parts has commenced, with the first parts having successfully undergone acceptance by Lockheed Martin. The contract shall also enable Lockheed Martin to obtain offset credits towards this platform sale.
“We are excited about the opportunity to partner with Rossell Techsys and confident of their vital capability to deliver high quality cable and harness assemblies in support of the India MRH Program and the Indian Navy,” said Hamid Salim, Vice President and General Manager, Sikorsky Maritime and Mission Systems.
About Lockheed Martin
Headquartered in Bethesda, Maryland, Lockheed Martin Corporation is a global security and aerospace company that employs approximately 114,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.
Present in India for over three decades, Lockheed Martin is proud of its longstanding relationships and commitment to customers and partners on existing and future programs ranging from transport, maritime and fighter aircraft, to sea and land-based air and missile defence projects, as well as capabilities in civil sectors including new and renewable energy. A strategic partner and developer of sovereign industrial, workforce and enterprise capability, Lockheed Martin India’s joint ventures, apprenticeships, and founding membership of the India Innovation Growth Program underscore its conviction in Indian industry, talent and progress.
Please follow @LMNews on Twitter for the latest announcements and news across the company.
About Rossell Techsys
Rossell Techsys is the Aerospace & Defense Division of Rossell India Limited, a public listed company. It is an MSME, certified to AS9100, ISO 9001, ISO 14001, ISO 45001, ISO 27001, ISO 37001 and is also ISO 31000 and NIST 800-171 compliant. It operates from a state-of-the-art 225,000 sq. ft., LEED Gold rated facility at Bangalore, providing custom engineering and manufacturing services. Core competencies are in Electrical Wiring and Interconnect Systems (EWIS), Electronic System and Systems Integration (ESSI), Test Equipment and After Market Product Support Services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110006132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom